Bone Turnover

BTMs are increasingly used in routine clinical management of osteoporosis, especially for monitoring therapy, in addition to their use in other metabolic bone disease, such as Paget’s disease of bone and osteomalacia:

• CTX-I and PINP have been designated as reference BTMs for use in the management of osteoporosis¹⁻³.
• Concentrations of bone turnover enzymes in blood provide reliable information of bone turnover in patients with impaired kidney function:
  • BAP is recommended for use in the assessment of bone disease in patient with CKD-MBD⁴.
  • TRAcP-5b seems to be the only resorption marker that is not influenced by decline or failure in kidney function or dialysis in patients with CKD⁵.

We provide a comprehensive portfolio of BTM immunoassays, fully automated CLIA and traditional technology, allowing laboratories to fulfil their roles in helping the clinicians to manage and improve patient outcomes.

1. www.iofbonehealth.org
2. Vasikaran S et al. Clin Chem Lab Med 2011 Aug; 49(8):1271–1274.
3. Bauer D et al. Osteoporos Int. 2012 Oct;23(10):2425-33
4. Ketteler M et al. Ann Intern Med. 2018 Mar 20;168(6):422-430.
5. Vasikaran S et al. Calcif Tissue Int. 2021 Nov 30